Aspira Women's Health
Aspira Women's Health is a technology company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Aspira Women's Health is a technology company.
Aspira Women's Health is a bio-analytical diagnostics company focused on women's health, developing and commercializing innovative blood tests to assess ovarian cancer risk in women with adnexal masses.[1][2] It serves physicians and patients by providing FDA-cleared products like Ova1®, Overa®, and the emerging OvaSuiteSM portfolio, which combine biomarkers, menopausal status, and imaging data to stratify risk, enable earlier detection, and optimize treatment—addressing the challenge of distinguishing benign masses from malignancies to reduce unnecessary surgeries.[1][2] With over 10 years of expertise, the company shows growth momentum through next-generation tests like OvaWatch, which studies suggest could reduce avoidable surgeries by supporting non-invasive monitoring.[2]
Aspira Women's Health traces its roots to Vermillion, founded around 2001 when it partnered with Johns Hopkins University to develop novel biomarkers for ovarian, breast, and prostate cancers.[3] Key milestones include a 2003 Department of Defense grant funding biomarker discovery, a 2005 joint agreement with Quest Diagnostics to accelerate Ova1® commercialization, and Vermillion's initial public offering that year on Nasdaq under VRML.[3] A pivotal moment came in 2009 with FDA clearance of Ova1®, the first proteomic multivariate index assay for ovarian malignancy risk assessment, marking a shift toward specialized gynecologic diagnostics and eventual rebranding to Aspira Women's Health.[1][3]
Aspira rides the trend of precision medicine in women's health, leveraging AI-driven biomarker analysis and multi-omics data to tackle ovarian cancer's high mortality from late detection—where adnexal masses are often misclassified.[1][2] Timing aligns with rising demand for non-invasive diagnostics amid advancing imaging tech and personalized care shifts, fueled by market forces like aging populations and post-pandemic emphasis on efficient triage.[2] By influencing clinical guidelines and reducing overtreatment, Aspira contributes to the broader ecosystem of biotech-healthtech convergence, partnering with institutions like Johns Hopkins to accelerate biomarker innovation.[3]
Aspira is poised to expand OvaSuiteSM adoption, with OvaWatch potentially transforming management of benign masses through monitoring, amid trends like AI-enhanced proteomics and value-based care that favor high-NPV tests.[2] Regulatory expansions, payer reimbursements, and data from ongoing studies could drive revenue growth, evolving its influence toward comprehensive ovarian risk platforms. This positions Aspira as a leader in revolutionizing women's health diagnostics, building directly on its pioneering Ova1® legacy.[1]